This S-1 is a routine resale registration with no immediate market impact, but it introduces potential overhang from the 3.17 million registered shares. Monitor for any cash exercise of the Series B warrants, which would provide a modest capital infusion but also dilute existing shareholders. The company's going concern warning and heavy customer concentration (Humana, FSSA) remain the primary risks.
Executive Summary
Syra Health Corp. filed an S-1 registration statement to register 3,171,100 shares of Class A common stock for resale by selling stockholders, which are issuable upon exercise of Series B warrants with a $0.64 exercise price. The company will not receive proceeds from the resale but could receive up to ~$2.03 million if all warrants are exercised for cash. The filing is a routine resale registration, but it highlights the company's ongoing need for capital, as its auditor has expressed substantial doubt about its ability to continue as a going concern, despite a recent swing to profitability in H1 2026.
Key Facts
- S-1 registers 3,171,100 shares of Class A common stock for resale by selling stockholders, issuable upon exercise of Series B warrants.
- Series B warrants have an exercise price of $0.64 per share and expire on September 13, 2029.
- Company will not receive proceeds from the resale; potential cash proceeds of ~$2.03 million if all warrants are exercised for cash.
- Revenue was $4,667,943 for H1 2026, $7,225,973 for FY2025, and $7,982,082 for FY2024.
- Net income was $491,221 for H1 2026, compared to net losses of $896,333 for FY2025 and $3,759,238 for FY2024.
- Cash and cash equivalents were $2,123,747 as of June 30, 2026, up from $1,614,733 at December 31, 2025.
- Accumulated deficit was $9,229,305 as of June 30, 2026.
- Independent auditor expressed substantial doubt about the company's ability to continue as a going concern.
- Customer concentration: Humana, Inc. accounted for 37% of H1 2026 revenue; FSSA accounted for 18%.
- Class A common stock trades on OTCQB under SYRA; closed at $0.91 on September 10, 2026.
Financial Impact
Potential gross proceeds of ~$2.03 million from warrant exercise; no proceeds from resale.
Risk Factors
- Going concern uncertainty with substantial doubt from auditor.
- Heavy customer concentration: Humana (37% of H1 2026 revenue) and FSSA (18%).
- Potential dilution from the 3.17 million shares registered for resale.
- History of net losses and accumulated deficit of $9.2 million.
- Stock trades on OTCQB, limiting liquidity and institutional interest.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001493152-26-042591 |
| Exhibit: ex5-1.htm | 0001493152-26-042591 |
| Exhibit: ex107.htm | 0001493152-26-042591 |
| Exhibit: ex23-1.htm | 0001493152-26-042591 |
| Document: 0001493152-26-042591-index-headers.html | 0001493152-26-042591 |
| Document: 0001493152-26-042591-index.html | 0001493152-26-042591 |
| Document: 0001493152-26-042591.txt | 0001493152-26-042591 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | EFFECT | $0.8500 $0.8300 | ▼ −2.35% | ▼ −1.20% | $0.8600 (+1.18%) |
Sep 14, 2026 6w ago | S-1 | $0.9400 $0.9600 | ▲ +2.13% | ▲ +1.31% | $0.8600 (−8.51%) |
Aug 11, 2026 11w ago | 8-K | $0.6650 $0.7800 | ▲ +17.29% | ▲ +17.70% | $0.8600 (+29.32%) |
Jun 1, 2026 21w ago | DEFA14A | $0.5100 $0.4900 | ▼ −3.92% | ▼ −0.96% | $0.8600 (+68.63%) |
May 7, 2026 24w ago | 8-K | $0.5000 $0.4390 | ▼ −12.20% | ▼ −13.70% | $0.8600 (+72.00%) |
Apr 24, 2026 26w ago | 10-K/A | $0.4180 $0.4100 | ▼ −1.91% | ▼ −2.31% | $0.8600 (+105.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers